Frank Diehl, Ph.D.
EVP, Product Solutions
Frank Diehl is a globally recognized leader who brings to Thrive deep experience in cancer biology and detection, having pioneered the use of circulating tumor DNA (ctDNA) to detect and track the progression of cancer. In addition to his internationally-recognized accomplishments as a scientist, Frank is a successful senior R&D and business leader in medical diagnostics.
Frank holds a Ph.D. in molecular pathology from Ruprecht-Karls University, in Heidelberg, Germany.
In 2008, he co-founded one of the world’s first liquid biopsy companies, Inostics, where he served as chief scientific officer through its acquisition by Sysmex and ultimately became CEO of Sysmex Inostics. In 2014, one of Frank’s breakthrough studies was recognized by the American Association for Cancer Research as one of the most important contributions to cancer research in the past century. He completed a postdoctoral fellowship at the Ludwig Center for Cancer Genetics and Therapeutics at Johns Hopkins University and worked in the laboratory of Thrive co-founders Drs. Bert Vogelstein and Kenneth Kinzler, where he developed the first quantitative DNA blood test for colorectal cancer screening.
Back to Who We Are